• 한국진공학회지
• /
• 제8권4A호
• /
• pp.476-481
• /
• 1999

Characteristics of platinum dry etching were investigated in a cryogenic magnetized inductively coupled plasma (MICP). The problem with platinum etching is the redeposition of sputtered platinum on the sidewall. Because of the redeposits on the sidewall, the etching of patterned platinum structure produces feature sizes that exceed the original dimension of the PR size and the etch profile has needle-like shape [1]. The main object of this study was to investigate a new process technology for fence-free Pt etching As bias voltage increased, the height of fence was reduced. In cryogenic etching, the height of fence was reduced to 20% at-$190^{\circ}C$ compared with that of room temperature, however the etch profile was not still fence-free. In Ar/$SF_6$ Plasma, fence-free Pt etching was possible. As the ratio of $SF_6$ gas flow is more than 14% of total gas flow, the etch profile had no fence. Chemical reaction seemed to take place in the etch process.

• 자원리싸이클링
• /
• 제27권3호
• /
• pp.93-99
• /
• 2018

본 연구에서는 디스플레이 산업의 백금 폐스크랩을 용해, 용매추출을 통하여 백금족 성분을 효율적으로 추출하고, 추출된 백금용액을 디젤자동차 배가스 정화촉매용 전구체 용액으로서 제조하고, 그 촉매활성을 실험하였다. 용액화학적 이론 연구를 통하여 백금 화학종의 수용액상 거동을 조사하였고, 화학종들의 존재영역 및 거동을 근거로 추출 및 분리 가능방안을 수립하였다. 전기화학적 방법에 의해 폐스크랩을 용해시킴으로써, 용해시간 단축 및 추출효율을 높였으며, 로듐 성분을 분리 제거, TBP에 의한 용매추출, 염산에 의한 탈거 공정을 거쳐 Pt-Chloride-$H_2O$ 계 백금용액을 용액을 제조하고, 이 용액을 원료로 액상 아민화 반응을 통해 아민산 백금용액을 제조한 다음, 카본블랙의 연소반응에 대한 촉매 활성을 실험함으로써, 백금족 폐스크랩으로부터 고부가 백금족 화합물의 제조가능성을 연구하였다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권11호
• /
• pp.4917-4920
• /
• 2016

For advanced non-small-cell lung cancer (NSCLC) cases, a platinum-based regimen is the first-line chemotherapy treatment. The excision repair cross-complementing group 1 (ERCC1) plays an important role in DNA repair and has been related to resistance to platinum chemotherapy. This study aimed to investigate the effects of the ERCC1 (C118T) polymorphism on treatment response in 26 Thai advanced NSCLC patients receiving first line platinum-based chemotherapy during January to July 2015 at King Chulalongkorn Memorial Hospital (KCMH). DNA was extracted from peripheral blood lymphocytes and the single nucleotide polymorphism of ERCC1 was genotyped using a real-time PCR method with the TaqMan assay. The distribution of C/C, C/T and T/T genotypes was 57.7 %, 34.6 % and 7.7 %, respectively. The response rate to platinum-based chemotherapy in the wild type (C/C) of ERCC1 (C118T) was better than with the variant types (C/T and T/T) but the difference was not statistically significant (29.7% vs 9.1%, P=0.274). The results showed that a genetic polymorphism in ERCC1 might influence patient response to platinum-based chemotherapy. Further multicenter studies are now required to confirm the results of our study.

• Advances in nano research
• /
• 제7권3호
• /
• pp.169-180
• /
• 2019

Plasmonic effects of gold and platinum alloy nanoparticles (Au-Pt NPs) and their comparison to size was studied. Various factors including ratios of gold and platinum salt, temperature, pH and time of addition of reducing agent were studied for their effect on particle size. The size of gold and platinum alloy nanoparticles increases with increasing concentration of Pt NPs. Temperature dependent synthesis of gold and platinum alloy nanoparticles shows decrease in size at higher temperature while at lower temperature agglomeration occurs. For pH dependent synthesis of Au-Pt nanoparticles, size was found to be increased by increase in pH from 4 to 10. Increasing the time of addition of reducing agent for synthesis of pure and gold-platinum alloy nanoparticles shows gradual increase in size as well as increase in heterogeneity of nanoparticles. The size and elemental analysis of Au-Pt nanoparticles were characterized by UV-Vis spectroscopy, XRD, SEM and EDX techniques.

• Radiation Oncology Journal
• /
• 제7권2호
• /
• pp.149-156
• /
• 1989

HeLa 세포의 spheroid를 배 양시켜 cis-platinum과 carboplatin으로 처리한 후 그 반응을 세포의 생존분획으로 분석하였다. 체외실험 model인 spheroid를 사용하여 platinum유사체의 약효와 방사선 감수성을 평가하고 약제에 대한 단층 세포와 spheroid의 감수성 차이를 세포-생존곡선에서 규명하기 위하여 본 실험을 시행하였다. Cis-platinum 농도-곡선에서 spheroid의 $Cq=3.4{\mu}M$이고 $Co=1.2{\mu}M$이었다. 이 것은 단층세포에 비하여 Co는 큰 변화가 없으나 Cq가 증가되어 cis-platinum이 저산소층 세포보다 활동적으로 분화하는 표면세포에 주로 작용하였으며, 반대로 carboplatin의 효과는 spheroid에 대한 $(Co=15.0{\mu}M)$ 감수성이 단층세포$(Co=32.5{\mu}M)$에 비하여 크게 증가되어, spheroid의 심층 세포에 주로 작용하였다. 방사선과 carboplation의 병용효과를 세포 생존분획이 0.01 수준에서 isobologram으로 분석한 결과 상호작용으로 supra-additive 효과를 나타내었다. 따라서, carboplatin은 cis-platinum에 비하여 신장과 위장에 대한 독성작용이 적고, 방사선과 병용함으로써 향후 더욱 효과적 인 종양 치료에 중요한 역할을 할 것으로 기대한다.

• 한국수소및신에너지학회논문집
• /
• 제25권3호
• /
• pp.219-226
• /
• 2014

In HI decomposition, $Pt/Al_2O_3$ has been studied by several researchers. However, after HI decomposition, it could be seen that metal dispersion of $Pt/Al_2O_3$ was greatly decreased. This reason was expected of platinum loss and sintering, which platinum was aggregated. Also, this decrease of metal dispersion caused catalytic deactivation. This study was conducted to find the condition to minimize platinum sintering and loss. In particular, heat treatment atmosphere and temperature were examined to improve the activity of HI decomposition reaction. First of all, although $Pt/Al_2O_3$ treated in hydrogen atmosphere had low platinum dispersion between 13 and 18%, it was shown to suitable platinum form that played an important role in improving HI decomposition reaction. Oxygen in the air atmosphere made $Pt/Al_2O_3$ have high platinum dispersion even 61.52% at $500^{\circ}C$. Therefore, in order to get high platinum dispersion and suitable platinum form in HI decomposition reaction, air heat treatment at $500^{\circ}C$ was needed to add before hydrogen heat treatment. In case of 5A3H, it had 51.13% platinum dispersion and improved HI decomposition reaction activity. Also, after HI decomposition reaction it had considerable platinum dispersion of 23.89%.

• Asian Pacific Journal of Cancer Prevention
• /
• 제14권12호
• /
• pp.7203-7206
• /
• 2013

Recent studies suggested that the ovarian cancers with negative excision repair cross-complementation group 1 enzyme (ERCC1) expression have a better response to platinum-based chemotherapy than those with positive ERCC1 expression. The objective of this study was to evaluate whether ERCC1 expression is associated with response to platinum-based chemotherapy in ovarian cancers. MEDLINE, PubMed, Web of Science and CNKI databases were used for searching studies relating to ERCC1 protein expression and response to platinum-based chemotherapy in ovarian cancers. Statistical analysis was based on the method for a fixed effects meta-analysis. Pooled odds ratios (ORs) with 95% confidence intervals for ERCC1 protein expression and response to platinum-based chemotherapy were generated. Publication bias was investigated with Begg's test. Five studies involving 306 patients with ovarian cancer were included. Compared to patients with positive ERCC1 expression, those with negative ERCC1 expression had a better response to platinum-based chemotherapy. The pooled OR was 5.264 (95% CI: 2.928-9.464, P < 0.001) and publication bias was not found (P = 0.904). The result was similar in both in Asians and Caucasians (P < 0.001 and P = 0.028, respectively). ERCC1 protein expression status is significantly associated with response to platinum-based chemotherapy in ovarian cancers.

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 1993년도 제2회 신약개발 연구발표회 초록집
• /
• pp.73-73
• /
• 1993

As part of a research program to develope 3rd generation anti tumor platinum complexes, a series of platinum complexes which have 4, 5-bis-(aminomethyl)- 1, 3-dioxolane derivatives as bidenate amine ligands, represented by the general structual formula was prepared. The R$_1$ and/or R$_2$ substituents in this series of platinum complexes can be hydrogen. alkyl, of jointly formed cyclohexane. Two Xs can be a bidenate leaving ligand such as 1, 1-cyclobutanedicarboxylate, malonate, dimethylmalonate, ethylmalonate, glycolate, L-lactate, or N-methyliminodiacetate. From based on the pharmacological and toxicological studies, we have chosen SKI 2053R, cis-malonato[(4R, 5R)-4, 5-bis(aminomethyl)-2-isopropyl-1, 3-dioxolane] platinum(II) complex (NSC D644591) as a candidate for clinical evaluation. The antitumor activity of a new anti tumor platinum complex, cis-malonato [(4R, 5R)-4, 5-bis(aminomethyl)-2-isopropyl-1, 3-dioxolane] platinum(II) (SKI 2053R, NSC D644591), was compared with those of cisplatin and carboplatin using murine tumors. We evaluated three platinum complexes against L1210/CPR, a subline of L1210 leukemia resistant to cisplatin for their abilities to overcome tumor resistance to cisplatin. The in vitro cytotoxicity of SKI 2053R to L1210 cell line was 2.5-fold less potent thann that of cisplatin, and was 10-fold more cytotoxic than that of carboplatin. SKI 2053R retained similar cytotoxic effect and anti tumor activity to L1210/CPR cell line, like the cytotoxicity of SKI 2053R to L1210 cell line, while either cisplatin or carboplatin had not property to overcome the acquired cisplatin-resistance. SKI 2053R exhibited greater or comparable antitumor activity than cisplatin or carboplatin in murine tumor models.

• Tuberculosis and Respiratory Diseases
• /
• 제81권2호
• /
• pp.148-155
• /
• 2018

Background: Although targeted therapy and immuno-oncology have shifted the treatment paradigm for lung cancer, platinum-based combination is still the standard of care for advanced non-small cell lung cancer (NSCLC). Pemetrexed continuation maintenance therapy has been approved and increasingly used for patients with nonsquamous NSCLC. However, the efficacy of this strategy has not been proven in patients without driving mutations. The objective of this study was to compare the clinical benefit of pemetrexed continuation maintenance to conventional platinum-based doublet in epidermal growth factor receptor (EGFR)-negative lung adenocarcinoma. Methods: A total of 114 patients with EGFR-negative lung adenocarcinoma who were treated with platinum doublet were retrospectively enrolled. We compared the survival rates between patients received pemetrexed maintenance after four-cycled pemetrexed/cisplatin and those received at least four-cycled platinum doublet without maintenance chemotherapy as a first-line treatment. Results: Forty-one patients received pemetrexed maintenance and 73 received conventional platinum doublet. Median progression-free survival (PFS), which was defined as the time from the day of response evaluation after four cycles of chemotherapy to disease progression or death, was significantly higher in the pemetrexed maintenance group compared to conventional group (5.8 months vs. 2.2 months, p<0.001). Median overall survival showed an increasing trend in the pemetrexed maintenance group (22.3 months vs. 16.1 months, p=0.098). Multivariate analyses showed that pemetrexed maintenance chemotherapy was associated with better PFS (hazard ratio, 0.73; 95% confidence interval, 0.15-0.87). Conclusion: Compared to conventional platinum-based chemotherapy, premetrexed continuation maintenance treatment is associated with better clinical outcome for the patients with EGFR wild-type lung adenocarcinoma.

• 자원리싸이클링
• /
• 제20권2호
• /
• pp.67-73
• /
• 2011

연료전지 폐스택으로부터 백금을 회수하여 재사용하기 위하여 백금의 농도, pH, 환원제, 분산제의 영향을 살펴본 결과 1 mM $H_2PtCl_6$:10 mM $NaBH_4$:8 mM Cl4TABr = 1:0.4:0.4(vol.%), pH4, $50^{\circ}C$, 160 rpm, 10분 조건에서 최적 백금 나노 입자 제조 조건을 확립하였다. 시용 후 폐기된 MEA로부터 산침출을 통해 회수되어진 백금 침출 용액으로부터 백금 모사 용액과 동일한 조건에서 5 nm 이하의 백금 나노 입자를 합성하였다. 백금 모사 용액과 백금 침출 용액으로부터 합성된 백금 나노 입자를 XPS 분석을 통해 백금 이온에서 zero-valent의 백금 나노 입자로 환원되었음을 확인하였다.